We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-15.48%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$504M
AUM Growth
-$158M
Cap. Flow
-$56.6M
Cap. Flow %
-11.24%
Top 10 Hldgs %
27.49%
Holding
102
New
6
Increased
45
Reduced
33
Closed
10

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$10M
2
ALKS icon
Alkermes
ALKS
+$9.75M
3
ENDP
Endo International plc
ENDP
+$6.8M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.86M
5
GILD icon
Gilead Sciences
GILD
+$5.05M

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$11.5M
2
MDT icon
Medtronic
MDT
+$8.44M
3
HNT
HEALTH NET INC
HNT
+$8.35M
4
ABMD
Abiomed Inc
ABMD
+$8.02M
5
CVS icon
CVS Health
CVS
+$7.29M

Sector Composition

Rank Sector Weight
1 Healthcare 93.13%
2 Financials 1.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
$16.8M 3.34%
121,000
+21,000
+21% +$3.08M
GILD icon
2
Gilead Sciences
GILD
$162B
$16.5M 3.28%
180,000
+56,000
+45% +$5.05M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$11.6B
$15.7M 3.11%
190,000
+72,000
+61% +$5.86M
PFE icon
4
Pfizer
PFE
$143B
$14.1M 2.79%
500,650
+38,998
+8% +$1.11M
LLY icon
5
Eli Lilly
LLY
$1.02T
$14M 2.79%
195,000
+49,000
+34% +$3.71M
ALKS icon
6
Alkermes
ALKS
$8.22B
$13.8M 2.75%
405,000
+247,000
+156% +$9.75M
INCY icon
7
Incyte
INCY
$24.2B
$12.3M 2.45%
170,000
+60,000
+55% +$4.47M
CELG
8
DELISTED
Celgene Corp
CELG
$12M 2.38%
120,000
+16,000
+15% +$1.65M
ABMD
9
DELISTED
Abiomed Inc
ABMD
$11.9M 2.35%
125,000
-95,000
-43% -$8.02M
AGN
10
DELISTED
Allergan plc
AGN
$11.3M 2.23%
42,000
-13,000
-24% -$3.72M
CVS icon
11
CVS Health
CVS
$133B
$10.9M 2.16%
105,000
-75,000
-42% -$7.29M
MDT icon
12
Medtronic
MDT
$109B
$10.3M 2.04%
137,000
-112,000
-45% -$8.44M
STJ
13
DELISTED
St Jude Medical
STJ
$9.9M 1.97%
180,000
+5,000
+3% +$272K
BIIB icon
14
Biogen
BIIB
$30B
$9.89M 1.96%
+38,000
New +$10M
ZBH icon
15
Zimmer Biomet
ZBH
$18.2B
$9.7M 1.93%
93,730
-16,480
-15% -$1.59M
CI icon
16
Cigna
CI
$73.7B
$9.47M 1.88%
69,000
-18,000
-21% -$2.47M
BMY icon
17
Bristol-Myers Squibb
BMY
$133B
$9.07M 1.8%
142,000
-41,000
-22% -$2.59M
LH icon
18
Labcorp
LH
$25B
$8.79M 1.74%
87,300
-6,984
-7% -$670K
CNC icon
19
Centene
CNC
$30.7B
$8.72M 1.73%
283,424
-14,576
-5% -$435K
MDVN
20
DELISTED
MEDIVATION, INC.
MDVN
$8.6M 1.71%
187,000
+27,000
+17% +$979K
WBA
21
DELISTED
Walgreens Boots Alliance
WBA
$8.42M 1.67%
100,000
-32,000
-24% -$2.56M
HCA icon
22
HCA Healthcare
HCA
$87.2B
$8.12M 1.61%
104,000
+8,000
+8% +$559K
ALNY icon
23
Alnylam Pharmaceuticals
ALNY
$27.5B
$7.85M 1.56%
125,000
+63,000
+102% +$4.19M
PRGO icon
24
Perrigo
PRGO
$1.4B
$7.8M 1.55%
61,000
-84,000
-58% -$11.5M
UNH icon
25
UnitedHealth
UNH
$376B
$7.73M 1.54%
60,000
-61,000
-50% -$7.22M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2016 Portfolio in Review

As of Q1 2016, Rhenman & Partners Asset Management held 102 positions worth $504M, down 24% from $661M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $56.6M in Q1 2016, closing 10 positions and reducing 33 holdings. Its most notable exit was HEALTH NET INC, an estimated $8.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Biogen worth $9.89M.

  • Rhenman & Partners Asset Management's largest Q1 2016 buy was Biogen: 38,000 shares worth $9.89M.
  • Rhenman & Partners Asset Management added most to Alkermes in Q1 2016, an estimated $9.75M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2016 reduction was Perrigo, cutting an estimated $11.5M.
  • Rhenman & Partners Asset Management fully exited HEALTH NET INC in Q1 2016, selling an estimated $8.35M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $504M portfolio in Q1 2016.
  • Rhenman & Partners Asset Management opened 6 new positions and closed 10 in Q1 2016.
  • Rhenman & Partners Asset Management's portfolio value fell 24% quarter-over-quarter to $504M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2016, filed 19 Apr 2016.